A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II

Jose De Leon, Neil B. Sandson, Kelly L. Cozza

Research output: Contribution to journalArticlepeer-review

37 Scopus citations
Original languageEnglish
Pages (from-to)347-361
Number of pages15
JournalPsychosomatics
Volume49
Issue number4
DOIs
StatePublished - 2008

Bibliographical note

Funding Information:
In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations.

Funding

In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations.

FundersFunder number
Eli Lilly Research Foundation
Roche Molecular Systems, Inc.
Eli Lilly and Company
Janssen Biotech

    ASJC Scopus subject areas

    • Arts and Humanities (miscellaneous)
    • Applied Psychology
    • Psychiatry and Mental health

    Fingerprint

    Dive into the research topics of 'A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II'. Together they form a unique fingerprint.

    Cite this